Market-patient access
pink-shape
Market &
Patient Access pillar-3 2
MARKET & PATIENT ACCESS

From Approval to Access.

Accelerating and optimising access to therapeutic innovation by combining global reach with deep local expertise.

By seamlessly integrating Market & Patient Access with cross-functional development capabilities, PLG supports life sciences companies in navigating complexity, shaping policy, and delivering sustainable value to healthcare systems and patients.

Achieving a successful regulatory approval is a critical milestone, but it does not guarantee patient access to your product.

In today’s complex global environment, developing a robust market access strategy is as demanding as the regulatory approval process itself. Payers, health technology assessment (HTA) bodies, and national healthcare systems require clear, compelling evidence of clinical and economic value before granting reimbursement.

In an increasingly complex and interconnected geopolitical landscape, successful pricing and reimbursement strategies demand early planning, deep local intelligence, and the ability to operate across regulatory, scientific, commercial, and policy dimensions simultaneously.

Shifting from transactional submissions to proactive access planning.

A major strategic liability for expanding biopharma companies is not planning for commercial access and treating it as an afterthought or a foregone conclusion. Waiting until Phase III or post registration to define your payer value proposition often results in delayed and inequitable patient access. To avoid the disappointment that comes with misaligned clinical endpoints and restrictive reimbursement criteria, sponsors require sophisticated market access strategies that begin early in clinical development and continue throughout the product life-cycle.

PLG addresses these challenges by deploying comprehensive global market access consulting services that align your clinical development programme with local commercial realities. We can advise how to strengthen your evidence package for different market archetypes and develop launch sequencing strategies to maximise your revenue. Our cross-functional teams translate complex evidence packages into compelling arguments that resonate with payers.

Backed by direct payer insights, extensive HTA experience and deep policy expertise, we help you build a resilient strategy that minimises time-to-market and secures sustainable pricing across multiple international jurisdictions.

Services

Technical Capabilities Across the Access Lifecycle

Our specialised teams deliver integrated support across five core operational pillars:

Market access & pricing strategy
Market access and pricing strategy

Strategic planning that optimizes launch sequence and pricing strategy, maximizes value. 

next-arrow
HTA and pricing & reimbursement
HTA and pricing & reimbursement

Expert navigation of HTA submissions and pricing negotiations, leveraging local knowledge. 

next-arrow
Health economics & modeling
Health economics & modeling

Rigorous economic modeling and analyses that deliver compelling evidence payers need, de-risking development.

next-arrow
Value evidence and medical strategy
Value evidence & medical strategy

Compelling value narratives combining clinical evidence and patient perspectives that resonate with stakeholders. 

next-arrow
Policy and advocacy
Policy & advocacy

Strategic stakeholder engagement and coalition-building that shapes favorable market environments, accelerates access. 

next-arrow
Guillaume Bouchara (1)

Market & Patient Access

Guillaume Bouchara
BU Managing Director

 

"Approval tells you a product can reach patients. Access decides whether it actually will.

Too often, the value story is written after the evidence is already fixed, and by then there is little room left to shape it.

We bring payer and HTA thinking into development early, and pair global strategy with people who know how each national system really decides.

That's how innovation becomes treatment patients can actually get."

 

Frequently asked questions

Market access is the process of securing pricing and reimbursement so that patients can actually obtain a product. Regulatory approval confirms a product can be marketed; payers, health technology assessment (HTA) bodies and national health systems then decide whether, and at what price, it is reimbursed. Without a clear value case, approved products can face delayed or restricted access.

During clinical development, well before Phase III. Waiting until registration often means clinical endpoints and comparators do not match what payers need, leading to restrictive reimbursement. PLG brings payer and HTA thinking into development early, so the evidence package is built for both regulators and payers.
Five integrated services: Market Access and Pricing Strategy, HTA and Pricing & Reimbursement, Health Economics & Modelling, Value Evidence & Medical Strategy, and Policy & Advocacy. Together they cover the journey from early value planning to national price negotiations and long-term access.
The JCA is the EU-level assessment of relative clinical effectiveness introduced by the EU HTA Regulation, which now applies to new oncology medicines and advanced therapies and will extend to more products over time. Its scope fixes comparators and outcomes at EU level. PLG runs regulatory strategy, JCA preparation and national pricing as one coordinated programme. See our Joint Clinical Assessment page.
Value-Added Medicines (VAM) are known molecules improved through new formulations, delivery routes or combinations that bring benefits to patients or health systems. Their incremental innovation is often under-recognised by payers. PLG helps build the evidence and value narrative to secure defensible pricing across global markets. See our Value-Added Medicines page.
It quantifies a product's value in economic terms through models such as cost-effectiveness and budget impact analyses. These are core inputs to HTA submissions in many countries. PLG's Health Economics & Modelling team builds rigorous models that give payers the evidence they need and help de-risk development decisions.

PLG pairs global strategists with local experts who know how each national system decides on pricing and reimbursement. This lets companies plan launch sequencing across markets, tailor evidence to different market archetypes and handle country-specific HTA and negotiation processes without losing a coherent global value story.